This is the first study to demonstrate both an increase in BAFF and APRIL levels in patients with IgG4-RD as well as the differential effects of GC treatment on BAFF and APRIL in patients with IgG4-RD. This evidence concerns the gene TNFSF13B and immunoglobulin G4-related sclerosing disease.